RadNet (RDNT) Q1 2026 earnings review
Outstanding Top-Line Acceleration Overshadows Persistent Digital Margin Drag
RadNet delivered an exceptionally strong first quarter, shrugging off an estimated $13 million weather-related revenue hit to post 22.1% YoY top-line growth. The core Imaging Center business is firing on all cylinders, driven by a highly favorable mix shift toward advanced imaging (MRI, CT, PET/CT). Adjusted EBITDA accelerated to 36.3% YoY growth, prompting management to raise full-year 2026 guidance. However, beneath the headline success, the rapidly expanding Digital Health segment is cannibalizing its own profitability, and an aggressive M&A spree has significantly drained cash reserves.
🐂 Bull Case
The mix shift to high-margin advanced imaging (MRI, CT, PET/CT) is accelerating, moving from 26.9% of total volume a year ago to 29.3%. This operating leverage drove a 52 basis-point margin expansion in the Imaging Center segment.
Annual Recurring Revenue (ARR) for the Digital Health division almost doubled YoY to $96.9 million, bolstered by the Gleamer SAS acquisition. RadNet expects to process over 70% of its studies through clinical AI by year-end.
🐻 Bear Case
Despite a massive 51.5% YoY revenue surge in the Digital Health segment ($29.1M), Adjusted EBITDA actually shrank by $2.4M down to a meager $1.3M. Scaling this software business is proving highly dilutive in the near term.
Cash and equivalents plummeted from $767M at year-end to $455M as the company spent aggressively on M&A ($304M). Meanwhile, GAAP net losses persist (-$33.5M), heavily clouded by add-backs like stock-based compensation and R&D.
⚖️ Verdict: 🟢
Bullish. The core imaging business is a cash-generating machine exhibiting accelerating growth, which provides a massive buffer. Even if the Digital Health segment bleeds cash in the short term, RadNet is cementing a structural moat through AI workflow dominance and aggressive footprint expansion.
Key Themes
Advanced Imaging Mix Shift is Accelerating
RadNet's core profit engine is running hot. Aggregate advanced imaging (MRI, CT, PET/CT) grew an impressive 19.7% YoY, heavily outpacing routine imaging. Same-center advanced volume grew 8.2%. This structural shift is the primary driver behind the 36.3% jump in total Adjusted EBITDA, proving that the strategy of capturing high-acuity diagnostics is highly accretive to margins.
Gleamer Acquisition Supercharges Digital ARR
The March acquisition of France-based Gleamer SAS immediately transformed the Digital Health profile. Segment ARR spiked to $96.9 million (vs $49.8M in 25Q1). By integrating Gleamer's capabilities alongside DeepHealth's Reporting Pro AI-powered auto-summarization engine, RadNet is building the industry's most comprehensive tech stack to solve radiology labor shortages.
Health System JVs: The Trinity Health Blueprint
The new joint venture with Trinity Health's Saint Alphonsus Health System (5 centers in Idaho) acts as a trojan horse. Management is using the physical JV to embed the entire DeepHealth OS and AI solutions into the partner's network. This 'land and expand' model provides a highly scalable blueprint for future hospital system partnerships.
Digital Health Profitability Contradicts the Momentum Narrative
Management boasts about the momentum and $16M in new third-party contracts for DeepHealth, but the actual segment financials are reversing. Digital Health revenue jumped 51.5% to $29.1M, but segment Adjusted EBITDA fell by $2.4M YoY to $1.3M. The cost to integrate acquisitions, build commercial infrastructure, and fund R&D is severely diluting the segment's bottom line.
Aggressive Capital Deployment Drains Liquidity
RadNet went on an M&A bender in Q1, deploying $304 million for acquisitions (including Gleamer). Consequently, cash reserves plunged 40% from $767 million at year-end to $455 million. While net debt to Adjusted EBITDA remains slightly below 2.0x, the rapid cash burn limits near-term strategic flexibility compared to previous quarters.
Macro: Severe Weather Remains a Seasonal Achilles Heel
Despite strong overall numbers, the business remains vulnerable to macro weather events. Management noted that winter weather in the Northeast reduced Q1 Revenue by $13 million and Adjusted EBITDA by $9 million. While the company outgrew this drag, it highlights the operational friction inherent in physical outpatient networks.
Other KPIs
Accelerating. Up significantly from $41.5 million in 25Q1. This massive 90% YoY improvement in cash generation indicates excellent working capital management and validates the high cash-conversion nature of the core imaging center growth.
Stable. Improved slightly from a $(37.9) million loss in 25Q1. The loss is heavily driven by elevated stock-based compensation ($31.4M), depreciation/amortization ($45M), and $17.7M in interest expenses. Real operating leverage has yet to reach the unadjusted bottom line.
Guidance
Accelerating. Management raised the midpoint by $30 million. Assuming the $2.38B midpoint, this implies approximately 18% YoY growth over FY25's estimated imaging baseline, indicating supreme confidence in advanced imaging volume durability.
Accelerating. The midpoint was raised by $5 million to $346.5 million. RadNet is passing through its increased volume directly to the bottom line, easily absorbing the prior $30M+ structural labor cost headwinds mentioned in 2025.
Accelerating. Raised by $7 million at the midpoint. This implies roughly 56% YoY FCF growth compared to the $75 million generated in FY25, highlighting stellar operational conversion.
Stable. Management maintained original guidance despite the strong Q1 showing. This implies a 51% YoY growth rate at the midpoint, matching Q1's actual growth pace.
Key Questions
Digital Health Margin Trough
With Digital Health Adjusted EBITDA shrinking YoY despite 50%+ revenue growth, when exactly do we expect operating leverage to kick in for the SaaS portfolio? What is the timeline for Gleamer to become EBITDA positive?
Capital Allocation Pause?
After deploying over $300 million in Q1 and drawing down cash balances significantly, are you hitting pause on large-scale M&A to digest Gleamer and the new JV centers, or does the pipeline demand further near-term capital?
Labor Cost Update
In 2025, you cited structural wage inflation for radiology technologists as a primary headwind. Are the Q1 EBITDA margin expansions a result of tech solutions (like TechLive) finally offsetting these labor costs, or are we simply outgrowing the wage inflation via volume?